FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington,	D.C.	20548

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Cleveland Paul B						SANGAMO BIOSCIENCES INC [SGMO]										(Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANAL BLVD					10	/21/20)13			`	h/Day/Year) ed (Month/Da		Officer (give title below) 6. Individual or Joint/Group Fi				Other (s below)	pecify			
(Street) RICHMOND CA 94804												X									
(City)	(S	tate)	(Zip)																		
		Tab	le I - I	Non-Der	ivativ	e Sec	urit	ies A	cquire	d, D	isposed o	f, or B	eneficia	ally (Owned						
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					Benefic Owned		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)		
Common Stock			10/21/2	10/21/2013				M		10,000	Α	\$4.5	4 10		,000		D				
Common	Stock			10/21/2	2013				S ⁽¹⁾		10,000	D	\$10.93	36 ⁽²⁾	6 ⁽²⁾ 0 D			D			
		-	Table								posed of, convertil				wned						
Derivative Conversion Date Execuserity or Exercise (Month/Day/Year)		if any	tion Date, Trans		saction of Derivative Securities Acquired (A) or Disposed of (D) (Inst. 3, 4 and 5)		vative urities uired or oosed O) (Instr.	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se	Price of erivative ecurity istr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owners Form: Direct (I or Indire (I) (Instr	Ownership	Beneficial Ownership ct (Instr. 4)			
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amour or Number of Shares	er							
Stock Option (Right to Buy)	\$4.54	10/21/2013			М			10,000	(3	3)	06/01/2020	Common Stock	10,00	0	\$0.00	0		D			

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2013.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$10.82 to \$11.12, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- 3. All shares underlying this option are vested and immediately exercisable

/s/ Florence Tam, Attorney-in-

<u>Fact</u>

** Signature of Reporting Person Date

10/23/2013

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.